尼塞韦单抗对婴儿呼吸道合胞病毒相关重症监护室入住的有效性——美国24个州,2024年12月至2025年4月
在美国27家医院的病例对照研究中,评估尼塞韦单抗对婴儿呼吸道合胞病毒(RSV)相关ICU入住和急性呼吸衰竭的有效性。457例RSV阳性病例中14%在症状出现前≥7天接受过尼塞韦单抗,302例RSV阴性对照中45%接受过。尼塞韦单抗对RSV相关ICU入住的有效性为80%(95%CI=70%-86%),对急性呼吸衰竭的有效性为83%(95%CI=74%-90%)。
要点
- 尼塞韦单抗对婴儿RSV相关ICU入住的有效性为80%(95%CI=70%-86%)。
- 尼塞韦单抗对RSV相关急性呼吸衰竭的有效性为83%(95%CI=74%-90%)。
- 病例组14%和对照组45%在症状出现前≥7天接受过尼塞韦单抗。
核心结论
- 这些估计支持使用尼塞韦单抗作为预防策略,以保护婴儿免受RSV感染的严重结局。
研究设计与样本
- 27家医院的病例对照研究,评估2024年12月1日至2025年4月15日期间尼塞韦单抗对RSV相关婴儿ICU入住和入院后急性呼吸衰竭的有效性。
- 病例为457例RSV检测阳性并因呼吸道症状入住ICU的患儿,对照为302例RSV检测阴性的患儿。
主要发现
- 病例组中14%和对照组中45%在症状出现前≥7天接受过尼塞韦单抗。
- 尼塞韦单抗对RSV相关ICU入住的有效性为80%(95%CI=70%-86%),对急性呼吸衰竭的有效性为83%(95%CI=74%-90%)。
- 针对ICU入住终点,尼塞韦单抗接种距症状出现的中位时间为52天(IQR=32-89天);针对急性呼吸衰竭终点,中位时间为50天(IQR=32-86天)。
关键数值与推荐
- 2023年8月,CDC免疫实践咨询委员会推荐尼塞韦单抗用于保护所有在首个RSV流行季出生或进入首个RSV流行季的<8月龄婴儿,预防RSV相关下呼吸道感染。
临床怎么用
- 这些估计支持使用尼塞韦单抗作为预防策略,以保护婴儿免受RSV感染的严重结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory syncytial virus (RSV) is a leading cause of intensive care unit (ICU) admission and respiratory failure among infants (children aged <1 year) in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, to protect against RSV-associated lower respiratory tract infection among all infants aged <8 months born during or entering their first RSV season. Following licensure, nirsevimab effectiveness has been demonstrated against RSV-associated infant hospitalization, but evidence regarding effectiveness against RSV-associated critical illness is limited. In a 27-hospital case-control investigation, nirsevimab effectiveness against both RSV-associated infant ICU admission and acute respiratory failure (illness requiring continuous positive airway pressure, bilevel positive airway pressure, or invasive mechanical ventilation) after hospital admission was evaluated during December 1, 2024-April 15, 2025. Among 457 case-patients who received a positive RSV test result and 302 control patients who received a negative RSV test result admitted to an ICU with respiratory symptoms, 14% and 45%, respectively, had received nirsevimab ≥7 days before symptom onset. Nirsevimab was 80% effective (95% CI = 70%-86%) against RSV-associated ICU admission and 83% effective (95% CI = 74%-90%) against acute respiratory failure when received a median of 52 days (IQR = 32-89 days) and 50 days (IQR = 32-86 days) before onset for each respective endpoint. These estimates support the recommendation for use of nirsevimab as a prevention strategy to protect infants against severe outcomes from RSV infection.
引用
- Zambrano LD, Simeone RM, Newhams MM, et al. Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025. MMWR Morb Mortal Wkly Rep. 2025. PMID: 41348586. doi:10.15585/mmwr.mm7437a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。